Merck to Help Produce Johnson & Johnson’s Covid-19 Vaccine
Merck entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/Covid-19 medicines and vaccines.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Agilent Adds Liquid Biopsy Assay
/in Acquisitions, Assays, Breakthrough Device Designation, Business, Diagnostic Tools, Liquid Biopsies, Precision Oncology, Testing, TissueAgilent Technologies, expanding on the company’s precision oncology testing, is acquiring Resolution Bioscience.
FDA Accepts NDA for Oyster Point’s Dry Eye Therapy
/in Business, Clinical Data, Clinical Trials, Dry Eye Disease, FDA, Immunosuppressants, Nasal Sprays, New Drug Applications, R&D, Secondary Endpoints, StocksOyster Point’s New Drug Application (NDA) for the dry eye disease therapy OC-01 was accepted for FDA regulatory review on the back of positive Phase III data.
U.S. trial of Covid-19 blood plasma halted after no benefit found
/in Blood Plasma, Clinical Trials, Convalescent Plasma, COVID-19 Plasma, National Institutes of Health, R&D, Symptoms: Coronavirus Disease 2019 (COVID-19)The U.S. National Institutes of Health (NIH) halted a trial of convalescent blood plasma in the treatment of patients with mild-to-moderate Covid-19 symptoms as it was unlikely to benefit this group.
FDA Advisory Panel Meeting for Anemia Drug
/in Advisory Panels, Anemia, AstraZeneca, Business, Cardiovascular and Renal Drugs Advisory Committee, Chronic Kidney Disease, Clinical Trials, FDA, Japanese Ministry of Health, New Drug Applications, Partnership, R&DThe U.S. Food and Drug Administration decided to put together an advisory committee meeting of outside experts to review a New Drug Application (NDA) for FibroGen and partner AstraZeneca’s investigational anemia therapy roxadustat.
Novavax: Covid-19 Vaccine U.S. EUA Possible by May
/in Business, Clinical Trials, COVID-19 Vaccinations, Emergency Use Authorization (EUA), FDA, Interim Data, Novavax, Partnership, Quarterly results, R&D, United StatesNovavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration could grant Emergency Use Authorization (EUA) for the company’s Covid-19 vaccine by May.
Biden takes steps to help Merck boost Johnson & Johnson Covid-19 vaccine supply
/in Business, Collaborations, Defense Production Act, Facilities/Sites/Manufacturing, Janssen COVID-19 Vaccine (J&J), Joe Biden, Johnson & Johnson, Manufacturing, Manufacturing Plants, Merck, PartnershipsMerck & Co. will help make rival Johnson & Johnson’s Covid-19 vaccine in order to boost the slower-than-promised production of the one-dose shot, U.S. President Joe Biden said on March 2.
COVAX vaccine program to deliver 237 million doses to 142 nations by end of May
/in Africa, AstraZeneca, Business, Congo, Coronavirus Vaccines, COVAX Facility, Gavi, Ghana, Ivory Coast, Low-Income Countries, Middle-Income Countries, Nigeria, Serum Institute of India, World Health OrganizationCOVAX will deliver 237 million doses of AstraZeneca’s Covid-19 shot to 142 countries by the end of May as the World Health Organization-backed program steps up the global roll-out of its vaccine supplies.
Fauci says U.S. must stick to two-shot strategy for Pfizer, Moderna Covid-19 vaccines: paper
/in BNT162b2 (Pfizer and BioNTech), COVID-19 shots, COVID-19 Vaccines, Covid-19 Variant, Dr. Anthony Fauci (Director), Health Officials, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Pfizer, Science, The Washington Post, U.S. government, United KingdomThe United States must stick to a two-dose strategy for the Pfizer-BioNTech and Moderna Covid-19 vaccines, top U.S. infectious disease official Anthony Fauci told the Washington Post newspaper.
WHO panel issues strong advice against hydroxychloroquine for Covid-19
/in Anti-Inflammatory, Antimalarial, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Infections, Donald Trump, Hydroxychloroquine, The BMJ, WHO guidelines, World Health OrganizationThe drug hydroxychloroquine, once touted by Donald Trump as a pandemic “game-changer,” should not be used to prevent Covid-19 and has no meaningful effect on patients already infected, a World Health Organization expert panel said.